Mark Messmer

Interagency Coordination in Export Controls Act of 2026

This bill authorizes specified departments to propose regulations on U.S. export controls. It also directs the Department of State to evaluate China's military-civil fusion strategy (a national strategy to eliminate barriers between China's civilian commercial sector and its military and defense industrial sectors).

Specifically, the bill authorizes the State Department and the Departments of Defense and Energy to propose new rules or amendments to existing rules under the Export Administration Regulations. These departments may submit proposals directly to the Export Administration Review Board (EARB), which reviews applications for export licenses. The EARB must vote to accept or reject the proposal within 30 days of the proposal's submission, but the bill allows a 30-day extension.

The Department of Commerce's Bureau of Industry and Securities (BIS) must initiate the rulemaking process for each proposal accepted by a simple majority vote of the EARB.

BIS must also coordinate (instead of consult) with these departments on activities related to U.S. export controls.

The bill also requires the State Department, within 30 days of the bill's enactment, to complete a review of the implications of China's military-civil fusion strategy on U.S. export control policy and national security. The State Department must consider proposing to the EARB (or any successor entity) any change to U.S. export control policy identified pursuant to the review. The EARB must vote on the adoption of each proposal.

The State Department must report to Congress on the activities required by the bill.

North Platte Canteen Congressional Gold Medal Act

This bill provides for the award of a Congressional Gold Medal to recognize the individuals and communities that provided financial and other support for the North Platte Canteen in North Platte, Nebraska, during World War II.

No Antisemitism in Education Act of 2026

This bill requires local educational agencies (LEAs) and institutions of higher education (IHEs), as a condition of receiving federal funds, to treat discrimination that is motivated by antisemitism as vigorously as the LEA or IHE treats all other forms of discrimination prohibited by Title VI of the Civil Rights Act of 1964. (Title VI of the Civil Rights Act of 1964 prohibits discrimination based on race, color, or national origin in federally funded programs or activities.)

The bill requires federal agencies, LEAs, and IHEs to consider the definition of antisemitism contained in a December 11, 2019, executive order when reviewing or investigating whether a discriminatory act or omission was motivated by discriminatory antisemitic intent. The executive order incorporates the International Holocaust Remembrance Alliance's (IHRA's) working definition of antisemitism. According to the IHRA's working definition, antisemitism is a certain perception of Jews, which may be expressed as hatred toward Jews.

Leveling the Playing Field 2.0 Act

This bill addresses unfair trade practices by making various changes to U.S. antidumping and countervailing duty laws. Antidumping laws provide relief to U.S industries and workers that are materially injured or threatened with injury due to imports of like products sold in the U.S. market at less than fair value, while countervailing duty laws provide such relief from imports of products subsidized by a foreign government or public entity.

Specifically, the bill establishes a process for successive antidumping and countervailing duty investigations. Successive investigations may be concurrent (an ongoing investigation of the same product) or recently completed (not more than two years before the date of the initiation of the successive investigation). Further, the bill establishes a timeline for the Department of Commerce to issue determinations in successive investigations.

Among other provisions, the bill authorizes Commerce to

• apply countervailing duty law to subsidies provided by a foreign government or public entity to a company operating in a different country,

• use another method for calculating the cost of production in specific circumstances, and

• require importers to certify that the imported merchandise is not subject to an antidumping or countervailing duty order.

Additionally, the bill statutorily establishes procedures for Commerce to conduct circumvention inquiries, including by specifying the deadlines for preliminary and final determinations.

The bill also provides statutory authority for Commerce to investigate currency undervaluation as a countervailable subsidy.

Chip Security Act

This bill requires covered integrated circuit products (e.g., advanced computing chips) to incorporate certain security mechanisms.

Specifically, the bill directs the Department of Commerce to require any covered integrated circuit product to have chip security mechanisms that implement location verification before the product is exported, reexported, or in-country transferred to or in a foreign country.

Commerce must require any person that has received a license or other authorization under the Export Control Reform Act of 2018 to export, reexport, or in-country transfer a covered product to promptly report to Commerce's Bureau of Industry and Security if the person obtains credible information that the product has been diverted away from its intended location or has been subjected to tampering.

Additionally, Commerce must conduct an assessment and report to Congress on whether additional chip security mechanisms should be adopted. If Commerce determines additional security measures are necessary, then Commerce must require any covered product to include the secondary chip security mechanisms before the product is exported, reexported, or in-country transferred to or in a foreign country.

The bill authorizes Commerce to take certain enforcement actions, such as verifying the ownership and location of a covered product that has been exported, reexported, or in-country transferred to or in a foreign country.

Commerce must, within two years of the bill's enactment and annually thereafter for three years, assess new chip security mechanisms and report to Congress.

Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2025 or the SAFE Drugs Act of 2025

This bill provides for increased oversight of drug compounding and imposes statutory limits on compounded drugs that are essentially copies of commercially available drugs.

Currently, subject to certain requirements, compounded drugs (i.e., drugs that are mixed or altered to meet patient needs) do not require Food and Drug Administration (FDA) approval. Additional limits apply to the compounding of drugs that are essentially copies of commercially available drug products.

Under the bill, a compounded drug is essentially a copy of a commercially available drug product if (1) the compounded drug contains any active ingredient found in a commercially available drug product, and (2) there is no change made for an individual patient that results in a significant difference between the compounded drug and the commercially available drug. (The FDA’s current definition of the term also addresses dosage strength and route of administration.)

The bill increases the frequency at which a licensed pharmacist or physician may compound a drug that is essentially a copy of a commercially available drug to 20 times per month. Current FDA policy allows four such prescriptions per month.

The bill also imposes annual reporting requirements on physicians, facilities, and pharmacies (except hospital-based pharmacies) that compound certain drug products for out-of-state patients more than 20 times per month. Further, the bill subjects certain large-scale outsourcing facilities (i.e., FDA-registered facilities that compound in bulk) to regular inspection and reporting requirements.

This resolution expresses support for police officers and other law enforcement personnel.

The resolution further recognizes

• law enforcement officers across the United States in the pursuit of preserving safe and secure communities;

• the need to ensure that such officers have the equipment, training, and resources necessary to protect their health and safety while they are protecting the public; and

• the law enforcement community for acts of sacrifice and heroism.

The resolution expresses condolences and appreciation to the loved ones of each law enforcement officer who has made the ultimate sacrifice in the line of duty.

No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025

This bill modifies provisions relating to federal funding for, and health insurance coverage of, abortions.

Specifically, the bill prohibits the use of federal funds for abortions or for health coverage that includes abortions. Such restrictions extend to the use of funds in the budget of the District of Columbia. Additionally, abortions may not be provided in a federal health care facility or by a federal employee.

Historically, language has been included in annual appropriations bills for the Department of Health and Human Services (HHS) that prohibits the use of federal funds for abortions—such language is commonly referred to as the Hyde Amendment. Similar language is also frequently included in appropriations bills for other federal agencies and the District of Columbia. The bill makes these restrictions permanent and extends the restrictions to all federal funds (rather than specific agencies).

The bill's restrictions regarding the use of federal funds do not apply in cases of rape, incest, or where a physical disorder, injury, or illness endangers a woman's life unless an abortion is performed. The Hyde Amendment provides the same exceptions.

The bill also prohibits qualified health plans from including coverage for abortions. Currently, qualified health plans may cover abortion, but the portion of the premium attributable to abortion coverage is not eligible for subsidies.

Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025

This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.

Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.

The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.

The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)

Medicare Home Health Accessibility Act

This bill allows individuals to receive occupational therapy as a home health service under Medicare without the need for other services. Currently, individuals may only receive occupational therapy as a home health service if they first qualify for home health services based on other needs (e.g., physical therapy).